BIOMAT Database Logo BIOMAT Database Logo

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. 1986

J Harenberg, and B Würzner, and R Zimmermann, and G Schettler

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011479 Protamines A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692) Protamine,Protamine Sulfate,Protamine Chloride,Chloride, Protamine,Sulfate, Protamine
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis.
January 1992, Nephron,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Pharmacological studies on the low molecular weight heparin derivative CY 216.
July 1990, Die Pharmazie,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).
July 1985, Seminars in thrombosis and hemostasis,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
[Prophylactic and therapeutic use of a low molecular weight heparin fraction, CY 216].
January 1987, Journal des maladies vasculaires,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine.
July 1985, Seminars in thrombosis and hemostasis,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits.
June 1987, Thrombosis research,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction.
January 1988, Folia haematologica (Leipzig, Germany : 1928),
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY 216 and CY 222).
July 1990, Thrombosis research,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits.
September 1986, Thrombosis research,
J Harenberg, and B Würzner, and R Zimmermann, and G Schettler
[Recent data on the mechanism of action of the low molecular weight heparin fraction CY 216].
October 1986, Medizinische Klinik (Munich, Germany : 1983). Supplement,
Copied contents to your clipboard!